Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

67.00EUR
22 Feb 2019
Change (% chg)

€-0.90 (-1.33%)
Prev Close
€67.90
Open
€67.93
Day's High
€68.40
Day's Low
€67.00
Volume
2,851,688
Avg. Vol
3,405,771
52-wk High
€103.74
52-wk Low
€58.34

Chart for

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 22.18 30.48 33.70
EPS (TTM): 5.29 -- --
ROI: 8.69 14.95 14.45
ROE: 16.39 16.27 15.96

German stocks - Factors to watch on Feb. 19

BERLIN/FRANKFURT, Feb 19 The following are some of the factors that may move German stocks on Tuesday:

Feb 19 2019

Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

FRANKFURT German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology.

Feb 15 2019

UPDATE 1-Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

* Bayer gains full control over drug Vitrakvi (larotrectinib)

Feb 15 2019

Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

FRANKFURT, Feb 15 German drugmaker Bayer acquired all rights it does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly's Loxo Oncology.

Feb 15 2019

Bayer stresses drug's tolerability in bid for prostate cancer market

FRANKFURT Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.

Feb 14 2019

Bayer stresses drug's tolerability in bid for prostate cancer market

FRANKFURT, Feb 14 Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.

Feb 14 2019

Lawsuit says Monsanto's Roundup falsely suggests no harm to people, pets

Monsanto Co was sued on Wednesday by retail consumers who claim the Bayer AG unit misled them into buying the popular weed killer Roundup by falsely suggesting on labels it would not impede a bacteria that helps keep people and pets healthy.

Feb 13 2019

German stocks - Factors to watch on Feb. 12

BERLIN, Feb 12 The following are some of the factors that may move German stocks on Tuesday:

Feb 12 2019

Exclusive: Bayer's Monsanto wins arbitration ruling over royalties from Indian seed company

NEW DELHI German drugmaker Bayer AG's Monsanto unit has won proceedings against Indian seed maker Nuziveedu Seeds Ltd (NSL) in a royalty dispute, lawyers familiar with the matter said.

Feb 11 2019

Exclusive: Brazil soy farmers say Bayer violating court ruling in patent dispute

SAO PAULO Germany's Bayer AG is in violation of a Brazilian court order obliging it to deposit in escrow royalties paid by Mato Grosso state farmers for its Intacta RR2 Pro soy seed technology, farmers claimed on Friday.

Feb 08 2019

Earnings vs. Estimates